Co-Diagnostics

Co-Diagnostics PP&E per Employee

The PP&E per Employee of Co-Diagnostics (CODX) as of Oct 29, 2026 is 22,082.46 USD. In the previous year, PP&E per Employee was 16,810.57 USD — a change of 31.36% (higher).

PP&E per Employee

22,082.46USD

YoY

31.36%

Last updated:

PP&E per Employee of Co-Diagnostics is 2022 22,082.46 USD. PP&E per Employee of Co-Diagnostics was 2021 16,810.57 USD. It decreases by 31.36% higher compared to the previous year.

The Co-Diagnostics PP&E per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PP&E per Employee
Date
PP&E per Employee
Jan 1, 2015
979.83 USD
Jan 1, 2016
760.25 USD
Jan 1, 2017
1,439.71 USD
Jan 1, 2018
1,357.72 USD
Jan 1, 2019
1,711.58 USD
Jan 1, 2020
8,257.73 USD
Jan 1, 2021
16,810.57 USD
Jan 1, 2022
22,082.46 USD
The Co-Diagnostics PP&E per Employee history
YEARPP&E per EmployeeYoY
22,082.46USD+31.36%
16,810.57USD+103.57%
8,257.73USD+382.46%
1,711.58USD+26.06%
1,357.72USD-5.69%
1,439.71USD+89.37%
760.25USD-22.41%
979.83USD+201.65%
324.82USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

PP&E per Employee of Co-Diagnostics is 22,082.46 USD in 2022.

PP&E per Employee of Co-Diagnostics changed from 16,810.57 USD to 22,082.46 USD, representing a 31.36% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of PP&E per Employee Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

PP&E per employee measures the physical capital intensity per worker. Higher values indicate more capital-intensive operations.

PP&E per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track PP&E per Employee's Co-Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Co-Diagnostics

All Key Metrics — Co-Diagnostics